• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ENDOLOGIX AFX2; BIFURCATED STENT GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ENDOLOGIX AFX2; BIFURCATED STENT GRAFT Back to Search Results
Model Number BEA28-90/I16-30
Medical Device Problem Code Material Puncture/Hole (1504)
Health Effect - Clinical Codes Aneurysm (1708); Failure of Implant (1924)
Date of Event 11/23/2021
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
The devices involved in this event will not be returned for evaluation and remain implanted in the patient.Patient medical records and imaging studies will be requested for further evaluation by a clinical specialist.If additional information pertinent to the incident is obtained, a follow-up report will be submitted.Device iteration is afx2.
 
Event or Problem Description
The patient was initially treated for an abdominal aortic aneurysm (aaa) with implant of an afx2 bifurcated stent graft, an afx vela infrarenal.Approximately two and a half (2.5) years post initial procedure routine follow up computed tomography identified aneurysm enlargement and a type 3b endoleak.Reintervention is scheduled; however, has not yet taken place.The patient is reported to be stable.
 
Event or Problem Description
The patient was initially treated for an abdominal aortic aneurysm (aaa) with implant of an afx2 bifurcated stent graft, an afx vela infrarenal.Approximately two and a half (2.5) years post initial procedure routine follow up computed tomography identified aneurysm enlargement and a type 3b endoleak.Reintervention is scheduled; however, has not yet taken place.The patient is reported to be stable.Additional information: the clinical assessment determined that there was evidence to reasonably suggest sac growth of 7mm occurred that was not included in the event as reported.The sac growth was discovered during a review of the computed tomography (ct) scan reports.Reintervention was completed and the physician elected to implant an afx2 bifurcated stent graft.The final patient status was reported to be doing well following a secondary endovascular procedure.
 
Additional Manufacturer Narrative
The reported adverse event/incident was investigated in alignment with endologix operating procedures and work instructions.Where possible, it is endologix practice to make at least three good faith efforts to retrieve a reported adverse event/incident-related device as well as medical records and medical imaging.An evaluation of the manufacturing record was completed.A review of the part number/lot number combination needed for device identification shows the device to have been properly manufactured and released in accordance with the device master record.The review confirms there were no manufacturing or processing non-conformities identified that would contribute to the reported adverse event/incident.The device was not returned to endologix for evaluation because it remains implanted.A clinical evaluation of the adverse event/incident was completed.An examination of medical records and/or medical imaging received by endologix shows the type 3b endoleak of the bifurcated stent graft was confirmed.This is consistent with the reported adverse event/incident.The clinical evaluation also determined that there was evidence to reasonably suggest sac growth of 7mm occurred that was not included in the event as reported.The sac growth was discovered during a review of the computed tomography (ct) scan reports.Procedure-related harms, device, user, procedure, or anatomy-relatedness of this complaint could not be determined with the medical records available for review.The final patient status was reported as doing well following a secondary endovascular procedure.No additional investigation of this reported adverse event/incident is planned.However, should additional information relevant to the investigation outcome become available, a follow-up report will be submitted.Endologix will continue to monitor this and similar adverse events/incidents.Device iteration is afx2.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AFX2
Common Device Name
BIFURCATED STENT GRAFT
Manufacturer (Section D)
ENDOLOGIX
2 musick
irvine CA 92618
Manufacturer (Section G)
ENDOLOGIX
2 musick
,
irvine CA 92618
Manufacturer Contact
gary kirchgater
2 musick
,
irvine, CA 92618
8009832284
MDR Report Key12940624
Report Number2031527-2021-00483
Device Sequence Number4962343
Product Code MIH
UDI-Device Identifier00818009014597
UDI-Public(01)00818009014597(17)190817
Combination Product (Y/N)N
Initial Reporter StateFL
Initial Reporter CountryUS
PMA/510(K) Number
P040002
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2021
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Other,Health Professional,Company Representative
Initial Reporter Occupation Physician
Remedial Action Other,Recall
Type of Report Initial,Followup
Report Date (Section B) 11/23/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date08/17/2019
Device Model NumberBEA28-90/I16-30
Device Lot Number1968693005
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Initial
Initial Date Received by Manufacturer 11/23/2021
Supplement Date Received by Manufacturer01/21/2022
Initial Report FDA Received Date12/06/2021
Supplement Report FDA Received Date01/24/2022
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured09/13/2018
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
If action reported to FDA under 21 USC 360i(g), list
FDA-assigned Recall Number or include a statement
Z-0007-2019
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
AFX VELA INFRARENAL (LN 1932426005)
Outcome Attributed to Adverse Event Other; Required Intervention;
Patient Age81 YR
Patient SexMale
-
-